New coumarins and anti-inflammatory constituents from the fruits of Cnidium monnieri

  • Int J Mol Sci. 2014 May 28;15(6):9566-78. doi: 10.3390/ijms15069566.
Tzong-Huei Lee  1 ,  Yuan-Chih Chen  2 ,  Tsong-Long Hwang  3 ,  Chih-Wen Shu  4 ,  Ping-Jyun Sung  5 ,  Yun-Ping Lim  6 ,  Wen-Lung Kuo  7 ,  Jih-Jung Chen  8
Affiliations
  • 1. Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei 110, Taiwan. [email protected].
  • 2. Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Pingtung 907, Taiwan. [email protected].
  • 3. Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan. [email protected].
  • 4. Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. [email protected].
  • 5. National Museum of Marine Biology and Aquarium, Pingtung 944, Taiwan. [email protected].
  • 6. School of Pharmacy, College of Pharmacy, China Medical University, Taichung 404, Taiwan. [email protected].
  • 7. Chung-Jen College of Nursing, Health Science and Management, Chiayi 600, Taiwan. [email protected].
  • 8. Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Pingtung 907, Taiwan. [email protected].
PMID: 24879527 DOI: 10.3390/ijms15069566
Abstract

The fruit of Cnidium monnieri is commercially used as healthcare products for the improvement of impotence and skin diseases. Three new Coumarins, 3'-O-methylmurraol (1), rel-(1'S,2'S)-1'-O-methylphlojodicarpin (2), and (1'S,2'S)-1'-O-methylvaginol (3), have been isolated from the fruits of C. monnieri, together with 14 known compounds (4-17). The structures of these new compounds were determined through spectroscopic and MS analyses. Compounds 1, 4-12, and 14-17 exhibited inhibition (IC50 ≤ 7.31 µg/mL) of superoxide anion generation by human neutrophils in response to formyl-l-methionyl-l-leucyl-l-phenylalanine/cytochalasin B (fMLP/CB). Compounds 7, 9-11, 15, and 17 inhibited fMLP/CB-induced Elastase release with IC50 values ≤7.83 µg/mL. This investigation reveals that bioactive isolates (especially 6, 7, 14, and 17) could be further developed as potential candidates for the treatment or prevention of various inflammatory diseases.

Products